Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer (PASCART)
Recruitment status was Not yet recruiting
Patients undergoing lung resection due to pulmonary cancer can be compromised in their postoperative period due to atrial fibrillation.
A retrospective analysis performed at our institution indicates that 30 % of the population develope atrial fibrillation in the postoperative period.
Amiodarone is known to diminish the occurence of postoperative atrial fibrillation after heart surgery, why this drug is chosen as a prophylactic agent for the mentioned population.
Amiodarone is administrated twice a day for 5 days at a dose of 600 mg oral treatment after an initial loading bolus og 300 mg intravenously.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial|
- Free of atrial fibrillation [ Time Frame: 31082009 ] [ Designated as safety issue: Yes ]
- Cost-benefit analysis of amiodarone prophylactic [ Time Frame: 31082009 ] [ Designated as safety issue: No ]
|Study Start Date:||August 2008|
|Estimated Study Completion Date:||December 2009|
|Estimated Primary Completion Date:||August 2009 (Final data collection date for primary outcome measure)|
intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
Please refer to this study by its ClinicalTrials.gov identifier: NCT00724581
|Contact: Lars R Zebis, MD||+45 firstname.lastname@example.org|
|Contact: Thomas Decker, MD||+45 89495566|
|Aarhus University Hospital, Skejby||Not yet recruiting|
|Aarhus, Denmark, DK-8200|
|Contact: Lars R Zebis, MD, Ph.D. +45 89495566 email@example.com|
|Contact: Thomas D Christensen, MD, Ph.D. +45 89495566|
|Principal Investigator: Lars R Zebis, MD, Ph.D.|
|Principal Investigator:||Lars R Zebis, MD, Ph.D.||Aarhus University Hospital Skejby|